These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27681712)

  • 1. Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience.
    Hou Y; Shen R; Chaudhary S; Gao F; Li Z
    Acta Cytol; 2016; 60(5):481-489. PubMed ID: 27681712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies.
    Ferguson J; Chamberlain P; Cramer HM; Wu HH
    Diagn Cytopathol; 2013 Jul; 41(7):575-81. PubMed ID: 22807465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
    Serra P; Sanz-Santos J; Castellà E; Cirauqui B; Andreo F; Llatjós M; Avila M; Margelí M; Serrano L; Centeno C; Quiroga V; Torky M; Ruiz-Manzano J
    Cytopathology; 2018 Feb; 29(1):35-40. PubMed ID: 29119620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.
    Acs B; Szekely N; Szasz AM; Lotz G; Szekely T; Istok R; Szekely E; Madaras L; Kulka J; Jaray B
    Diagn Cytopathol; 2016 Jun; 44(6):466-71. PubMed ID: 26990933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.
    Garuti A; Rocco I; Cirmena G; Chiaramondia M; Baccini P; Calabrese M; Palermo C; Friedman D; Zoppoli G; Ballestrero A
    Gynecol Oncol; 2014 Feb; 132(2):389-96. PubMed ID: 24269902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer.
    Nakayama Y; Nakagomi H; Omori M; Inoue M; Takahashi K; Maruyama M; Takano A; Furuya K; Amemiya K; Ishii E; Oyama T
    Breast Cancer; 2016 Jul; 23(4):633-9. PubMed ID: 25968348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
    Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
    Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.